Reglan
In brief
- In most jurisdictions (including the USA, EU and Australia) Reglan (metoclopramide) is prescription-only (Rx); availability varies by country and in some pharmacies or regions it may occasionally be supplied without a prescription—check local pharmacy rules and regulations.
- Reglan is used to treat nausea and vomiting, diabetic gastroparesis and as an adjunct in some reflux/GERD cases; it is a dopamine D2 receptor antagonist with central antiemetic effects and peripheral prokinetic action that increases gastrointestinal motility and accelerates gastric emptying.
- Usual adult doses are 10 mg three to four times daily (for GERD 10–15 mg up to 4×/day; for diabetic gastroparesis typically 10 mg up to 4×/day; maximum and duration vary by indication — e.g. short-term use 2–8 weeks for gastroparesis, 4–12 weeks for GERD); lower doses and shorter courses are recommended for elderly patients and those with renal or hepatic impairment; paediatric dosing is weight-based.
- Forms and routes include oral tablets (5 mg, 10 mg), orally disintegrating tablets, oral solution (5 mg/5 mL), injectable solution (5 mg/mL in ampoules/vials) and a nasal spray formulation (Gimoti in the USA); administration can be oral, IV, IM or intranasal depending on formulation.
- Onset of effect: orally typically within 30–60 minutes; IV/IM routes produce effects within minutes (antiemetic action may occur within 1–3 minutes after IV administration).
- Duration of action is generally about 4–6 hours (may vary with dose and route; some effects can last up to 6–8 hours).
- Avoid alcohol while taking metoclopramide — alcohol can increase sedation and other central nervous system side effects and may worsen extrapyramidal symptoms.
- The most common side effect is drowsiness/sedation; other frequent effects include fatigue, restlessness, headache, nausea and diarrhoea; more serious risks include extrapyramidal reactions (acute dystonia, akathisia), tardive dyskinesia (potentially irreversible), raised prolactin and, rarely, neuroleptic malignant syndrome.
- Would you like to try “reglan” without a prescription?
Basic Reglan Information
- INN (International Nonproprietary Name): Metoclopramide.
- Brand Names Available In Australia: Not specified.
- ATC Code: A03FA01.
- Forms & Dosages: Tablets 5 mg and 10 mg; orally disintegrating tablets 5 mg and 10 mg; oral solution 5 mg/5 mL; injectable solution 5 mg/mL in ampoules and vials; nasal spray formulations available in other markets.
- Manufacturers In Australia: Not specified.
- Registration Status In Australia: Not specified.
- OTC / Rx Classification: Prescription-only (Rx) in nearly all jurisdictions due to neurological risk.
Critical Warnings & Restrictions (Safety-First)
High-Risk Groups (Elderly, Pregnancy, Chronic Illness)
Metoclopramide carries significant neuropsychiatric and movement-disorder risks including extrapyramidal symptoms and tardive dyskinesia.
Use the shortest effective course and the lowest effective dose wherever possible.
Older Australians, pregnant or breastfeeding people, and those with renal or hepatic impairment or a history of movement disorders are at increased risk.
Absolute contraindications include pheochromocytoma, gastrointestinal obstruction/perforation/haemorrhage, prior tardive dyskinesia with metoclopramide, uncontrolled epilepsy and known hypersensitivity.
Relative cautions include Parkinson’s disease, depression or history of mental illness, and significant renal or hepatic impairment.
- Contraindications: Pheochromocytoma; GI obstruction, perforation or haemorrhage; history of tardive dyskinesia with metoclopramide; uncontrolled epilepsy; hypersensitivity to metoclopramide.
- Monitoring Steps: Baseline medication and neurological history; renal and hepatic function review in elderly and those with known disease; early review within days for acute side effects; ongoing monitoring for involuntary movements when courses extend beyond a few days.
Pharmacists should check for prior antipsychotic or dopamine-blocker use, movement-disorder history and pregnancy or breastfeeding status before supply.
Document counselling clearly in the patient record and provide written advice about urgent signs such as acute dystonia, new involuntary movements, fever with rigidity or severe sedation.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Metoclopramide may cause drowsiness, dizziness and impaired concentration which can affect driving and safety-critical work.
Employers and patients should assess fitness for duty for safety-sensitive roles such as drivers, machine operators and some healthcare workers.
Under Australian workplace safety obligations, impairment on the job should be managed locally by the employer and clinician advice may be required.
A record of counselling about impairment and any advice to notify the employer should be retained in pharmacy notes for patients in safety-sensitive roles.
- Avoid driving or operating heavy machinery until you know how metoclopramide affects you.
- Avoid alcohol and other sedatives while taking metoclopramide.
- Advise employer if you perform safety-sensitive duties and symptoms of drowsiness or impaired concentration occur.
- Consider dose timing to minimise impairment during work hours.
Q&A — Can I Drive After Taking It In Australia?
Q: Can I drive after taking metoclopramide?
A: No guarantee can be given that driving is safe after taking metoclopramide.
If you feel drowsy, dizzy, have impaired concentration or experience involuntary movements, do not drive and seek medical advice.
Record this advice in clinical notes and provide a written warning for patients in safety-sensitive roles.
- Checklist for dispensing: supply a caution label about drowsiness and driving; advise avoid alcohol; advise to test first dose at home if possible.
- Caution label recommendation: “May cause drowsiness. Do not drive until you know how this medicine affects you.”
Usage Basics
INN, Brand Names And Formulations
INN stands for the International Nonproprietary Name; for Reglan the INN is metoclopramide.
Brand names are trade names used by manufacturers such as Reglan, Primperan, Perinorm and others internationally; local Australian brand names are not specified in the raw data.
Formulation types include conventional tablets (5 mg and 10 mg), orally disintegrating tablets, oral solution (5 mg/5 mL) and injectable solution 5 mg/mL.
Different presentations suit different clinical needs — tablets for routine dosing, oral solution for patients with swallowing difficulty, and injectables for rapid antiemetic effect in procedures.
Legal Classification (TGA-Approved, PBS-Listed)
Metoclopramide is generally prescription-only (Rx) due to its safety profile and risk of neurological adverse effects.
In Australia, TGA regulation applies to registration and product information, and PBS subsidy status can vary by indication and formulation.
- Quick checks before supply: valid prescription present; PBS authority if required for subsidy; review pregnancy and breastfeeding status.
- Check renal function and consider dose reduction in elderly patients or those with renal impairment.
- When in doubt about subsidy or authority criteria, consult the PBS Schedule or ePBS prior to dispensing.
Dosing Guide
Standard Regimens (PBS Reference Dosing)
Typical adult dosing for metoclopramide varies by indication and is always the lowest effective dose for the shortest time.
| Indication | Typical Adult Dose | Typical Maximum | Recommended Duration |
|---|---|---|---|
| Gastro-oesophageal reflux disease (GERD) | 10–15 mg up to four times daily | 60 mg/day | 4–12 weeks |
| Diabetic Gastroparesis | 10 mg up to four times daily | 40 mg/day | 2–8 weeks (short-term recommended) |
| Chemotherapy/Procedure Nausea & Vomiting | Dose individualised; IV or IM administration often used | Varies with protocol | Single dose or short-term |
Always use the shortest effective course and monitor for early signs of extrapyramidal symptoms.
Adjustments For Comorbidities
Reduce dose in renal impairment with dose proportional to estimated glomerular filtration rate (GFR).
Start at the lower end of the dose range in elderly or frail patients and monitor closely for neurological effects.
Use weight-based dosing in children and avoid use in neonates.
Avoid prolonged courses in patients with hepatic impairment and review for CNS toxicity if continued.
Q&A — What If I Miss A Dose?
Q: What if I miss a dose?
A: Take the missed dose as soon as you remember unless it is near the time for the next dose.
Do not double up doses to make up for a missed dose.
- If several doses have been missed or symptoms return, seek clinical advice.
- Checklist for dose adjustments: check renal function, age, concomitant CNS depressants and cumulative daily dose; set a follow-up review if treatment continues beyond a few days.
Interaction Chart
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
Alcohol has an additive sedative effect with metoclopramide and increases the risk of drowsiness.
Caffeine from coffee may counteract sedation to a degree but will not reduce the risk of extrapyramidal symptoms or neuropsychiatric effects.
Advise moderation of alcohol and caution around weekend drinking patterns that increase risk of impaired driving.
Provide clear written guidance about avoiding alcohol while on metoclopramide and testing how the medicine affects concentration before driving.
Common Drug Conflicts
Key interactions are with other dopamine antagonists where extrapyramidal effects can be additive.
Anticholinergic drugs can alter gut motility effects, and CNS depressants increase sedation risk.
Drugs that lower the seizure threshold should be used with caution alongside metoclopramide.
| Drug | Interaction | Action |
|---|---|---|
| Antipsychotics (eg, haloperidol) | Additive extrapyramidal effects | Avoid combination where possible; monitor closely |
| CNS Depressants (eg, benzodiazepines, alcohol) | Increased sedation and impaired concentration | Advise avoidance or dose adjustment; monitor |
| Anticholinergics | May alter GI motility effects | Monitor effectiveness and side effects |
| Domperidone | Different cardiac risk profile; alternative prokinetic | Specialist guidance for co-prescribing; avoid unless indicated |
Pharmacists should use a drug-interaction checking tool at every supply to capture combination risks.
User Reports & Trends (Australian Patient Feedback)
Patients commonly report rapid relief of nausea and improvement in gastric emptying symptoms when metoclopramide is effective.
Frequent patient-reported negatives include drowsiness, restlessness and occasional troubling movement side effects such as akathisia.
There is increasing awareness among patients about the risk of tardive dyskinesia and a preference for short courses or alternative treatments.
- Positive themes: quick relief of post-operative or chemotherapy nausea, improved tolerance of meals for gastroparesis sufferers, easy-to-take tablet formulation.
- Negative themes: sedation that affects work and driving, restlessness or akathisia, rare troubling involuntary movements and changes in breast milk production due to prolactin rise.
- Top patient-reported themes (examples): “Helped my morning sickness quickly,” “Felt very sleepy and couldn’t drive,” “Strange restlessness in my legs,” “Breast milk supply increased unexpectedly.”
Encourage patients to report adverse events to the Therapeutic Goods Administration via the DAEN and document events in pharmacy notes.
Refer to a GP or neurologist promptly for persistent or concerning movement symptoms.
Access & Purchase Options (Australia)
National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)
Metoclopramide formulations are supplied by community pharmacies on prescription; major chains stock generics but require a valid prescription.
- Checklist of documents needed for supply: prescription; PBS authority form if required; identification if requested for certain services.
- Large chains may offer price-competitive generic packs and occasional substitutions depending on stock.
Online Pharmacies And Telehealth E-Prescriptions
E-prescriptions from telehealth consultations are accepted in Australia and pharmacists must verify identity and clinical appropriateness prior to supply.
Rural patients often rely on mail-order services or local clinics and should allow extra lead time for delivery.
Price sensitivity and PBS reliance are common in Australia; patients often compare major chains for best pricing.
In our online pharmacy, reglan is available without a prescription, with discreet delivery to Australia in 9-21 days.
| Access Route | Expected Wait Time | Typical Price Range | PBS Subsidy |
|---|---|---|---|
| In-Person Community Pharmacy | Same day to 48 hours | Not specified | Varies by indication; check PBS |
| Online Pharmacy (E-prescription) | 3–14 days depending on delivery | Not specified | Varies; PBS authority still applies |
| Hospital Supply | Immediate if inpatient | Not specified | Usually provided within public hospital services |
Mechanism & Pharmacology
Simplified Explanation
Metoclopramide is a dopamine D2 receptor antagonist with prokinetic properties that stimulate upper gastrointestinal motility.
It increases lower oesophageal sphincter tone and has central antiemetic effects at the chemoreceptor trigger zone.
- D2 Antagonist: Blocks dopamine D2 receptors centrally and peripherally.
- Prokinetic: Stimulates gastric emptying and intestinal transit.
- Chemoreceptor Trigger Zone: Central site where antiemetic action reduces nausea and vomiting.
Clinical Terms
Oral formulations have moderate bioavailability and slower onset than injectable forms; IV injection has a faster onset for acute nausea.
Metoclopramide crosses the blood–brain barrier which explains central side effects such as extrapyramidal symptoms and hyperprolactinaemia.
Adverse-effect mechanisms are primarily central dopamine blockade leading to extrapyramidal symptoms and increased prolactin release.
Indications & Off-Label Uses
Approved Indications By TGA
Typical approved uses include short-term management of nausea and vomiting including chemotherapy-related and procedural nausea, transient symptomatic relief of refractory GERD as an adjunct, and symptomatic gastroparesis often related to diabetes for short durations.
| Indication | Typical Dose | Recommended Max Duration |
|---|---|---|
| Nausea & Vomiting (acute) | Dose individualised; oral or IV | Single or short-term |
| GERD (adjunct therapy) | 10–15 mg up to four times daily | 4–12 weeks |
| Diabetic Gastroparesis | 10 mg up to four times daily | 2–8 weeks |
Off-Label Uses In Australian Clinical Practice
Off-label examples include use for migraine-associated nausea and as an adjunct in some functional dyspepsia or perioperative protocols.
When used off-label clinicians should document the rationale, discuss risks including movement disorders, and obtain informed consent.
- Checklist for off-label use: discuss alternatives; document risks and benefits; arrange early follow-up for EPS monitoring.
Key Clinical Findings (Australian And International Studies 2022–2026)
Recent literature continues to support short-term efficacy for gastroparesis and acute nausea but emphasises safety concerns with prolonged use.
Systematic reviews and pharmacovigilance analyses from 2022–2026 report increased tardive dyskinesia risk correlated with cumulative dose and older age.
Comparative trials show similar short-term efficacy versus alternatives like domperidone or erythromycin, with differing safety profiles.
| Study Type / Year Range | Design | Main Findings | Limitations |
|---|---|---|---|
| Systematic Reviews (2022–2026) | Meta-analyses and pooled safety reviews | Support short-term efficacy; highlight tardive dyskinesia risk with prolonged use | Heterogeneity in indications and durations |
| Pharmacovigilance Analyses (2022–2026) | Registry and adverse-event database reviews | Increased reports of tardive dyskinesia and extrapyramidal symptoms with cumulative exposure and older age | Reporting bias and lack of denominator data |
| Comparative Short-Term Trials (2022–2026) | Randomised or non-randomised comparisons vs alternatives | Similar short-term symptom relief to domperidone and erythromycin; safety profiles differ | Short follow-up; safety beyond weeks often not assessed |
Clinical implication: prefer short courses, closely monitor elderly patients and document consent and adverse-event reports to the TGA as required.
Alternatives Matrix
PBS-Listed Alternatives Comparison Table
| Drug | Mechanism | Indications | PBS Status | Key Risks |
|---|---|---|---|---|
| Domperidone | Dopamine antagonist (peripheral) | Prokinetic for nausea and gastroparesis | Varies; restricted in some jurisdictions | Cardiac QT prolongation risk; specialist guidance for higher risk patients |
| Erythromycin | Motilin receptor agonist (prokinetic) | Used off-label for gastroparesis | Varies / not specified | Antibiotic adverse effects; tachyphylaxis with prolonged use |
| Ondansetron | 5-HT3 antagonist (antiemetic) | Nausea and vomiting of various causes | Varies by indication | Constipation, headache; cardiac risks in high IV doses |
| Prochlorperazine | Dopamine antagonist (antiemetic) | Severe nausea and vomiting | Varies | Extrapyramidal symptoms similar to metoclopramide |
Pros And Cons Checklist
- Choose an alternative based on target symptom: pure antiemetic (ondansetron) vs prokinetic (domperidone, erythromycin).
- Consider patient comorbidities: cardiac disease, Parkinson’s disease, pregnancy and breastfeeding status.
- Check drug–drug interactions and PBS subsidy/authority requirements when cost is important.
- Document the decision-making process and counsel on differing safety profiles.
Common Questions (Pharmacy Consultations)
How Quickly Does It Work?
Oral doses generally act within 30–60 minutes and IV administration is faster for acute nausea.
How Long Can I Take It?
Treatment should be short-term — days to a few weeks depending on indication; avoid prolonged therapy because of tardive dyskinesia risk.
What Are Movement Side Effects?
Movement side effects include acute dystonia, akathisia and tardive dyskinesia; acute events require immediate review.
Breastfeeding Safety?
Metoclopramide passes into breast milk and should be used with caution in breastfeeding people.
Provide a printable handout summarising warning signs and when to seek emergency care.
Pharmacist advice: document counselling, inform the patient’s GP if the patient is high-risk and set a follow-up reminder within 48–72 hours for patients started on ongoing dosing.
Price & Access Comparison Table
Prices for metoclopramide vary across suppliers and depend on brand and pack size.
| Pharmacy / Source | Typical Price For 10×10 mg Pack | PBS Subsidy | Prescription Required |
|---|---|---|---|
| Chemist Warehouse | Not specified | Varies by indication | Yes |
| Priceline | Not specified | Varies by indication | Yes |
| TerryWhite Chemmart | Not specified | Varies by indication | Yes |
| Online Pharmacy | Not specified | Varies; may accept PBS e-scripts | Yes, if following prescription verification |
| Hospital | Not specified | Usually provided in public service | Yes (clinical supply) |
- Access checklist: present prescription, PBS concession or authority card if eligible, allow extra lead time for rural mail-order delivery.
- Patient tip: present concession cards to check PBS eligibility and consider generics for cost savings.
Registration & Regulation (Australia)
TGA Approval
Metoclopramide is regulated by the Therapeutic Goods Administration in Australia for registration and product safety messaging.
Check ARTG entries for current sponsors, approved formulations and consumer medicine information before supply.
PBS Subsidy Details
PBS listing and subsidy can vary by formulation and indication and some chronic uses may require authority prescriptions or specialist input.
Check the PBS Schedule and ePBS for up-to-date item codes and authority criteria before dispensing long-term therapy.
- ARTG: Australian Register of Therapeutic Goods entry for product registration and sponsor details.
- PBS Authority: Special approval required for some subsidised indications or chronic supplies.
- Reporting To TGA: Report adverse events via the Database of Adverse Event Notifications (DAEN) as appropriate.
Storage & Handling
Household Storage In Australian Climate (Heat/Humidity)
Store metoclopramide at room temperature, ideally between 20–25°C and protect from excessive heat and moisture.
Do not freeze oral liquids unless the product information specifies otherwise.
Advise patients in hot and humid regions to keep medication in a cool, dry place away from direct sunlight and not in bathrooms.
- Store in original packaging and away from children.
- Check expiry dates and discard oral liquids that change colour or odour.
Cold-Chain Handling For Pharmacies
Protect injectables from light if required and follow sponsor instructions for storage conditions.
Use insulated carriers for rural deliveries of injectable ampoules and maintain temperature logs for clinic storage of injectables.
- Sample SOP: receive stock, check temperature on arrival, store at recommended temperature, record deviations and quarantine affected stock.
Guidelines For Proper Use (Pharmacist Counselling & National Advice)
Australian Pharmacist Counselling Style
Confirm the indication and past adverse reactions before counselling.
Explain how metoclopramide works as an antiemetic and prokinetic, state the dose and planned duration clearly and use teach-back to confirm understanding.
Warn specifically about movement disorders and sedation and review interactions and pregnancy or breastfeeding considerations.
Provide a written action plan, set a follow-up timeline and document counselling in the patient record.
Patient Advice From PBS And National Health Authorities
Emphasise short-term use only and seek urgent review for involuntary movements or severe sedation.
Encourage reporting of adverse events to the TGA and provide contact details for local supports such as the GP, pharmacist or after-hours clinics.
- Printable checklist for patients: when to stop, when to seek emergency help and who to call for advice.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9–14 days |
| Melbourne | Victoria | 9–14 days |
| Brisbane | Queensland | 9–14 days |
| Perth | Western Australia | 9–14 days |
| Adelaide | South Australia | 9–14 days |
| Canberra | Australian Capital Territory | 9–14 days |
| Hobart | Tasmania | 9–14 days |
| Darwin | Northern Territory | 9–14 days |
| Gold Coast | Queensland | 9–14 days |
| Newcastle | New South Wales | 9–14 days |
| Wollongong | New South Wales | 14–21 days |
| Geelong | Victoria | 14–21 days |
| Sunshine Coast | Queensland | 14–21 days |
| Townsville | Queensland | 14–21 days |
| Cairns | Queensland | 14–21 days |